The rising prevalence of chronic diseases coupled with increasing research activities for cell-based research is found to be the major factor driving the...
Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on development of oncology, immunology, and critical care therapies, ...
Perfuse Therapeutics, a biopharmaceutical company pioneering transformational therapies to treat ischemia-induced ocular diseases announced today that the ...
-EU and UK filings completed in 2022; submissions validated by EMA and MHRA and the review procedure has begun as of January 2023- -Vertex Pharmac...
Therapeutic Solutions International (TSOI) Spin Off Company Campbell Neurosciences announced new data, covered by its previously filed patents, demonstrati...
“We are excited to begin working with Moderna on a specific application of our AI-enabled cryo-EM platform that leverages our technology infrastructu...
Under the terms of the agreement, Xeris will use its proprietary drug-formulation platform, XeriJect™, to develop ultra-highly concentrated, ready-to...
FILSPARI demonstrated a statistically significant, rapid, and sustained decline of proteinuria compared to the active control Travere Therapeutics, Inc. (...
With its resplendent flowers, the Madagascar periwinkle plant (Catharanthus roseus) easily draws attention to itself, both in a natural setting and in ...
AAVs make ideal gene therapy vectors due to their small size, genetic simplicity, and low immunogenicity. However, several limitations are hindering the wi...
More recently, the CRISPR system has been used to edit human induced pluripotent stem cells (iPSCs), which are known to exhibit phenotypes closer to human ...
Oligonucleotide therapeutics have unlocked new treatment possibilities for rare and fatal diseases often associated with undruggable proteins.1 Here, ...
Today, NEC and NOI announced that NOI will be realigned as a subsidiary of NEC Bio B.V. (NB) in Hilversum, Netherlands, a newly established wholly owned su...
Dermatology industry veteran Thibaud Portal, PhD appointed as CEO Granular Therapeutics, (Granular) a private biotech company specialising in p...
© 2025 Biopharma Boardroom. All Rights Reserved.
